Patents by Inventor Danfeng Kong

Danfeng Kong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11364299
    Abstract: A non-addictive analgesic sustained-release drug delivery system, comprising: (1) a narcotic analgesic drug having a concentration of 1 mg/ml-160 mg/ml, the drug being selected from a group consisting of: a local analgesic drug, and the combination of the local analgesic drug and a nonsteroidal analgesic drug and/or an opioid analgesic drug; (2) a drug menstruum in a proportion of 1%-75% (v/v), the menstruum being selected from a group consisting of benzyl alcohol, ethanol, benzyl benzoate, ethyl lactate, and tetrahydrofurfuryl polyethylene glycol ether; and (3) a drug sustained-release formulation having a proportion of 25%-99% (v/v), the sustained-release formulation being selected from a group consisting of natural vegetable oil, synthetic lipid, artificially improved half-natural lipid and derivative thereof. Also disclosed are a preparation process and use of the sustained-release drug delivery system.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: June 21, 2022
    Assignee: LIPONT PHARMACEUTICALS INC.
    Inventors: Tao Chen, Wudang Lu, Weiping Yu, Jianli Gao, Danfeng Kong, Qingchuan Zhao, Weijiao Wang, Qinyuan Wu
  • Publication number: 20190314281
    Abstract: The present invention discloses a novel local anesthetic analgesic sustained-release drug delivery system. The system includes an internal aqueous phase, an external aqueous phase, an oil phase, an organic solvent, an isoosmotic regulator and a pH regulator. The internal aqueous phase includes an analgesic, a drug solvent and a drug solubilizer. The analgesic is selected from one of bupivacaine, levobupivacaine, ropivacaine, lidocaine and tetracaine, and the analgesic is in a free base form or an acid saline form; the drug solvent is selected from inorganic acid containing N or P; and the drug solubilizer is selected from one or more of saccharide and ring-shaped organic acid. The multivesicular liposome prepared in the present invention has the advantages of high encapsulation percentage and drug loading capacity, uniform grain size, and good sustained-release effect.
    Type: Application
    Filed: August 21, 2018
    Publication date: October 17, 2019
    Inventors: Yufan Ma, Tao Chen, Danfeng Kong
  • Publication number: 20150359891
    Abstract: A non-addictive analgesic sustained-release drug delivery system, comprising: (1) a narcotic analgesic drug having a concentration of 1 mg/ml-160 mg/ml, the drug being selected from a group consisting of: a local analgesic drug, and the combination of the local analgesic drug and a nonsteroidal analgesic drug and/or an opioid analgesic drug; (2) a drug menstruum in a proportion of 1%-75% (v/v), the menstruum being selected from a group consisting of benzyl alcohol, ethanol, benzyl benzoate, ethyl lactate, and tetrahydrofurfuryl polyethylene glycol ether; and (3) a drug sustained-release formulation having a proportion of 25%-99% (v/v), the sustained-release formulation being selected from a group consisting of natural vegetable oil, synthetic lipid, artificially improved half-natural lipid and derivative thereof. Also disclosed are a preparation process and use of the sustained-release drug delivery system.
    Type: Application
    Filed: April 10, 2013
    Publication date: December 17, 2015
    Inventors: Tao Chen, Wudang Lu, Weiping Yu, Jianli Gao, Danfeng Kong, Qingchuan Zhao, Weijiao Wang, Qinyuan Wu